ArticleEuropean journal of medical research2025
Ouabain-mediated IGF2BP2-GLS/NOS3 axis affects arginine metabolism in diffuse large B-cell lymphoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Our group has previously demonstrated that ouabain can contribute to the malignant progression of diffuse large B-cell lymphoma (DLBCL) by regulating insulin-like growth factor 2 mRNA binding protein (IGF2BP2) at the genetic level. However, its potential impact on DLBCL metabolism remains unclear. To investigate this, we introduced ouabain or IGF2BP2 knockdown into DLBCL cells and observed that both treatments influenced the arginine metabolic pathway, as revealed by non-targeted metabolomics analysis. We further found significant changes in two genes: nitric oxide synthase 3 (NOS3) and glutaminase (GLS), which were involved in arginine metabolism. And it confirmed that NOS3 and GLS are highly expressed in DLBCL and associated with shorter patient survival. Real-time quantitative PCR (RT-qPCR) indicated that the expression levels of NOS3 and GLS were regulated by IGF2BP2. Cell proliferation was inhibited after interference with GLS and NOS3. Cell cycle and apoptosis experiments revealed that interference with GLS and NOS3 can delay cell progression and promote cell apoptosis. In conclusion, our study reveals that ouabain can interfere with arginine metabolism via the IGF2BP2-GLS/NOS3 axis, contributing to the progression of DLBCL. This provides novel targeted therapeutic strategies and potential targets for DLBCL treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.